Dr. Claire de Oliveira joined the Canadian Partnership Against Cancer as Expert Lead, Cancer Economics in 2016. In this role, she develops health economics expertise within the Partnership and supports efforts to deepen the capacity to quantify the burden of cancer and assess the economic impact of a coordinated, pan-Canadian approach to cancer control. She also works across cancer control initiatives to quantify efficiencies and support efforts to improve the sustainability of the cancer control system. Dr. de Oliveira is also a member of the Partnership’s Analytic Capacity Building Committee.
In addition to her work at the Partnership, Dr. de Oliveira is a health economist at the Centre for Addiction and Mental Health; an assistant professor at the Institute of Health Policy, Management and Evaluation at the University of Toronto; and an adjunct scientist at the Institute for Clinical Evaluative Sciences. Her main areas of research include: the development of costing methodology, the measurement of the economic burden, and the assessment of value for money in cancer care.
Dr. de Oliveira holds membership with the Canadian Centre for Applied Research in Cancer Control and is one of the program leads for Health Technology Assessment. In addition, she is a collaborator at the Toronto Health Economics Technology Assessment Collaborative.
Dr. de Oliveira holds a Masters of Arts degree and a Doctorate degree in economics from McMaster University. She also holds a licentiate degree in economics from the University of Oporto in Portugal.
Areas of Expertise (6)
McMaster University: PhD, Economics 2008
McMaster University: MA, Economics 2004
- Canadian Centre for Applied Research in Cancer Control: Member
- Canadian Centre for Applied Research in Cancer Control: Program Lead, Health Technology Assessment
- Insititute for Health Policy, Management and Evaluation, University of Toronto: Assistant Professor
- Institute for Clinical Evaluative Sciences: Adjunct Scientist
Cancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada.
Cancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs...
Investments in medical research can result in health improvements, reductions in health expenditures and secondary economic benefits. These “returns” have not been quantified in Canada. Our objective was to estimate the return on cardiovascular disease research funded by public or charitable organizations...
The first year after cancer diagnosis is a period of intensive treatment and high cost. We sought to estimate costs for the 21 most common cancers in Ontario in the 3-month period before and the first year after diagnosis...